Vertex Pharmaceuticals annual operating expenses
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Operating Expenses Growth & History (VRTX)
Vertex Pharmaceuticals's operating expenses was $6.18B for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.18B | −$3.55B | −36.47% |
| 2024 | 2024-12-31 | $9.72B | $4.95B | +103.61% |
| 2023 | 2023-12-31 | $4.78B | $1.23B | +34.77% |
| 2022 | 2022-12-31 | $3.54B | −$345.1M | −8.88% |
| 2021 | 2021-12-31 | $3.89B | $1.27B | +48.79% |
| 2020 | 2020-12-31 | $2.61B | $195.6M | +8.09% |
| 2019 | 2019-12-31 | $2.42B | $414.6M | +20.70% |
| 2018 | 2018-12-31 | $2.00B | −$87.4M | −4.18% |
| 2017 | 2017-12-31 | $2.09B | $608.5M | +41.07% |
| 2016 | 2016-12-31 | $1.48B | $99.7M | +7.22% |
| 2015 | 2015-12-31 | $1.38B | $149.0M | +12.08% |
| 2014 | 2014-12-31 | $1.23B | −$499.9M | −28.85% |
| 2013 | 2013-12-31 | $1.73B | $489.4M | +39.36% |
| 2012 | 2012-12-31 | $1.24B | $10.4M | +0.84% |
| 2011 | 2011-12-31 | $1.23B | $393.7M | +46.90% |
| 2010 | 2010-12-31 | $839.4M | $123.5M | +17.26% |
| 2009 | 2009-12-31 | $715.9M | $77.7M | +12.17% |
| 2008 | 2008-12-31 | $638.2M | — | — |
Vertex Pharmaceuticals quarterly operating expenses
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.60B | $191.7M | +13.63% |
| Q1 2026 | 2026-03-31 | $1.46B | −$321.1M | −18.07% |
| Q4 2025 | 2025-12-31 | $1.52B | $55.5M | +3.79% |
| Q3 2025 | 2025-09-30 | $1.48B | $212.4M | +16.82% |
| Q2 2025 | 2025-06-30 | $1.41B | −$4.38B | −75.71% |
| Q1 2025 | 2025-03-31 | $1.78B | $568.6M | +47.05% |
| Q4 2024 | 2024-12-31 | $1.46B | $301.4M | +25.96% |
| Q3 2024 | 2024-09-30 | $1.26B | $136.3M | +12.10% |
| Q2 2024 | 2024-06-30 | $5.79B | $4.63B | +399.78% |
| Q1 2024 | 2024-03-31 | $1.21B | −$120.4M | −9.06% |
| Q4 2023 | 2023-12-31 | $1.16B | $175.3M | +17.78% |
| Q3 2023 | 2023-09-30 | $1.13B | $208.5M | +22.71% |
| Q2 2023 | 2023-06-30 | $1.16B | $330.1M | +39.86% |
| Q1 2023 | 2023-03-31 | $1.33B | $518.1M | +63.90% |
| Q4 2022 | 2022-12-31 | $985.9M | $38.4M | +4.05% |
| Q3 2022 | 2022-09-30 | $918.2M | $225.1M | +32.48% |
| Q2 2022 | 2022-06-30 | $828.1M | −$775.2M | −48.35% |
| Q1 2022 | 2022-03-31 | $810.8M | $166.6M | +25.86% |
| Q4 2021 | 2021-12-31 | $947.5M | $268.6M | +39.56% |
| Q3 2021 | 2021-09-30 | $693.1M | $13.3M | +1.95% |
| Q2 2021 | 2021-06-30 | $1.60B | $981.4M | +157.79% |
| Q1 2021 | 2021-03-31 | $644.2M | $11.8M | +1.87% |
| Q4 2020 | 2020-12-31 | $678.9M | $2.1M | +0.32% |
| Q3 2020 | 2020-09-30 | $679.8M | −$38.7M | −5.39% |
| Q2 2020 | 2020-06-30 | $621.9M | $86.3M | +16.12% |
| Q1 2020 | 2020-03-31 | $632.4M | $145.9M | +29.98% |
| Q4 2019 | 2019-12-31 | $676.8M | $56.7M | +9.14% |
| Q3 2019 | 2019-09-30 | $718.6M | $250.9M | +53.66% |
| Q2 2019 | 2019-06-30 | $535.6M | $60.7M | +12.78% |
| Q1 2019 | 2019-03-31 | $486.5M | $46.3M | +10.50% |
| Q4 2018 | 2018-12-31 | $620.1M | $178.3M | +40.34% |
| Q3 2018 | 2018-09-30 | $467.6M | −$363.7M | −43.75% |
| Q2 2018 | 2018-06-30 | $474.9M | $54.7M | +13.01% |
| Q1 2018 | 2018-03-31 | $440.3M | $43.4M | +10.93% |
| Q4 2017 | 2017-12-31 | $441.8M | $82.4M | +22.93% |
| Q3 2017 | 2017-09-30 | $831.3M | $452.0M | +119.18% |
| Q2 2017 | 2017-06-30 | $420.2M | $36.1M | +9.40% |
| Q1 2017 | 2017-03-31 | $396.9M | $34.3M | +9.45% |
| Q4 2016 | 2016-12-31 | $359.4M | −$50.1M | −12.24% |
| Q3 2016 | 2016-09-30 | $379.3M | $29.7M | +8.50% |
| Q2 2016 | 2016-06-30 | $384.1M | $62.3M | +19.35% |
| Q1 2016 | 2016-03-31 | $362.6M | $61.5M | +20.43% |
| Q4 2015 | 2015-12-31 | $409.5M | $122.7M | +42.75% |
| Q3 2015 | 2015-09-30 | $349.6M | $38.6M | +12.41% |
| Q2 2015 | 2015-06-30 | $321.8M | $12.5M | +4.05% |
| Q1 2015 | 2015-03-31 | $301.1M | −$24.8M | −7.61% |
| Q4 2014 | 2014-12-31 | $286.9M | −$61.3M | −17.60% |
| Q3 2014 | 2014-09-30 | $311.0M | −$14.2M | −4.37% |
| Q2 2014 | 2014-06-30 | $309.3M | −$23.8M | −7.14% |
| Q1 2014 | 2014-03-31 | $325.9M | −$400.6M | −55.14% |
| Q4 2013 | 2013-12-31 | $348.2M | $12.3M | +3.66% |
| Q3 2013 | 2013-09-30 | $325.2M | $18.8M | +6.14% |
| Q2 2013 | 2013-06-30 | $333.1M | $8.6M | +2.64% |
| Q1 2013 | 2013-03-31 | $726.6M | $405.4M | +126.22% |
| Q4 2012 | 2012-12-31 | $335.9M | $19.4M | +6.12% |
| Q3 2012 | 2012-09-30 | $306.4M | −$101.8M | −24.94% |
| Q2 2012 | 2012-06-30 | $324.5M | $49.6M | +18.05% |
| Q1 2012 | 2012-03-31 | $321.2M | $87.6M | +37.51% |
| Q4 2011 | 2011-12-31 | $316.5M | $84.3M | +36.33% |
| Q3 2011 | 2011-09-30 | $408.2M | $184.8M | +82.74% |
| Q2 2011 | 2011-06-30 | $274.9M | $73.7M | +36.64% |
| Q1 2011 | 2011-03-31 | $233.6M | $50.9M | +27.83% |
| Q4 2010 | 2010-12-31 | $232.2M | $51.5M | +28.54% |
| Q3 2010 | 2010-09-30 | $223.4M | $50.2M | +28.98% |
| Q2 2010 | 2010-06-30 | $201.2M | $25.0M | +14.17% |
| Q1 2010 | 2010-03-31 | $182.7M | −$3.2M | −1.70% |
| Q4 2009 | 2009-12-31 | $180.6M | — | — |
| Q3 2009 | 2009-09-30 | $173.2M | — | — |
| Q2 2009 | 2009-06-30 | $176.2M | — | — |
| Q1 2009 | 2009-03-31 | $185.9M | — | — |
Vertex Pharmaceuticals operating expenses trends
Over the last five fiscal years, Vertex Pharmaceuticals's operating expenses increased from $2.61B to $6.18B, a change of $3.56B. The latest reported quarter, Q2 2026, shows $1.60B.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗Community posts
Vertex adds detailed kidney-response data and launches patient-experience trial
Vertex ($VRTX) released additional Phase 3 RAINIER findings for povetacicept in IgA nephropathy. At week 36, 42.2% of treated participants achieved a urine protein-to-creatinine ratio below 0.5 grams per gram, compared with 6.2% receiving p ...
